The Biotech drug maker Amgen Inc. is reportedly close to buying the cancer drug maker Onyx Pharmaceuticals Inc. for about $10.5 billion.
The New York Times reported Saturday that Amgen would buy Onyx for $125 per share. It cited people who had been briefed on the matter. The two companies declined to comment.
Amgen’s drugs include Prolia for osteoporosis, Enbrel for rheumatoid arthritis and skin disorders, and Neulasta and Neupogen for fighting infection in cancer patients. The Thousand Oaks, Calif., company reported $17.27 billion in revenue in 2012.
Onyx markets a liver and kidney cancer pill called Nexavar through a partnership with Bayer AG. Sales totaled $861 million in 2012, and Onyx received $288 million in revenue from those sales. In July, regulators approved Onyx’s Kyprolis for multiple myeloma. Full story for BostonGlobe.com subscribers.